Preventing antimalarial drug resistance through combinations.
about
Malarone treatment failure not associated with previously described mutations in the cytochrome b geneCoartem: the journey to the clinicMonitoring of efficacy and safety of artemisinin-based anti-malarials for treatment of uncomplicated malaria: a review of evidence of implementation of anti-malarial therapeutic efficacy trials in TanzaniaTargeting Plasmodium falciparum Hsp90: Towards Reversing Antimalarial ResistanceMultiple dose study of interactions between artesunate and artemisinin in healthy volunteersTransmission intensity and drug resistance in malaria population dynamics: implications for climate changePlasmodium falciparum: differential selection of drug resistance alleles in contiguous urban and peri-urban areas of Brazzaville, Republic of CongoA population genetic model for the initial spread of partially resistant malaria parasites under anti-malarial combination therapy and weak intrahost competitionBenefits of using multiple first-line therapies against malaria.Combined chloroquine, sulfadoxine/pyrimethamine and primaquine against Plasmodium falciparum in Central Java, IndonesiaActive case detection, treatment of falciparum malaria with combined chloroquine and sulphadoxine/pyrimethamine and vivax malaria with chloroquine and molecular markers of anti-malarial resistance in the Republic of VanuatuUpdate on the efficacy, effectiveness and safety of artemether-lumefantrine combination therapy for treatment of uncomplicated malaria.Experimental evolution, genetic analysis and genome re-sequencing reveal the mutation conferring artemisinin resistance in an isogenic lineage of malaria parasites.The treatment of chloroquine-resistant malaria.In vitro interaction of lumefantrine and piperaquine by atorvastatin against Plasmodium falciparum.Efficacy of Artesunate + Sulphadoxine-Pyrimethamine (AS + SP) and Amodiaquine + Sulphadoxine-Pyrimethamine (AQ + SP) for Uncomplicated falciparum Malaria in Equatorial Guinea (Central Africa).An old enemy, a new battle plan. Perspective on combating drug-resistant malaria.Adherence to artemether-lumefantrine drug combination: a rural community experience six years after change of malaria treatment policy in Tanzania.Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria.Pharmacokinetics of mefloquine combined with artesunate in children with acute falciparum malaria.Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria.Mutations in cytochrome b resulting in atovaquone resistance are associated with loss of fitness in Plasmodium falciparum.Artemether-lumefantrine: an option for malaria.The evolution of drug-resistant malaria: the role of drug elimination half-lifeChallenges Associated with Scaling up Artemisinin Combination Therapy in Sub-Saharan Africa A Review ArticleThe effect of intermittent preventive treatment on anti-malarial drug resistance spread in areas with population movement.Comparative clinical trial of two-fixed combinations dihydroartemisinin-napthoquine-trimethoprim (DNP) and artemether-lumefantrine (Coartem/Riamet) in the treatment of acute uncomplicated falciparum malaria in Thailand.Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine.Early variations in plasmodium falciparum dynamics in Nigerian children after treatment with two artemisinin-based combinations: implications on delayed parasite clearance.Antimalarial drug resistance and combination chemotherapy.Ex vivo susceptibility of Plasmodium falciparum isolates from Dakar, Senegal, to seven standard anti-malarial drugsFrom bright ideas to tools: the case of malariaThe evolution of pyrimethamine resistant dhfr in Plasmodium falciparum of south-eastern Tanzania: comparing selection under SP alone vs SP+artesunate combination.A cost-effectiveness analysis of artemether lumefantrine for treatment of uncomplicated malaria in Zambia.Artemether-Lumefantrine Combination Therapy for Treatment of Uncomplicated Malaria: The Potential for Complex Interactions with Antiretroviral Drugs in HIV-Infected Individuals.Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects.Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum.Intravenous pharmacokinetics, oral bioavailability, dose proportionality and in situ permeability of anti-malarial lumefantrine in rats.Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adultsA prospective study of adverse drug reactions to artemisinin-based combination therapy in a tertiary care hospital in India.
P2860
Q21033786-13CE1382-1330-4C72-B82D-44A886FE1271Q21034131-9390989A-BC1C-4922-BF7E-C640E4064149Q26820807-44E263BD-1F95-43AB-8E81-4BB91C82400EQ26864290-1A6BC69A-5619-4985-BE69-4A70BC2695BAQ28362543-AF35C592-595F-4AD4-A565-60358CEC73B8Q28475943-F5F6097A-6EA6-4692-BBD9-F1BB8A61B48FQ28476554-BAB8BB08-4DDA-4E21-A266-1D9F77796F66Q28540567-688CA76C-0E28-4674-A029-A033234A3C5AQ30483653-556F81D2-5701-4246-A451-055ABA863C54Q33263597-D787C8A8-4A4B-437B-BF95-40B684F62A6AQ33549954-2632C691-0666-446A-B8BE-302013F5071CQ33635019-E472C636-D009-4CFE-97E8-A07B4BEEF38EQ33693947-79959B3D-DD6B-496C-B4D1-2A16D3146446Q33711587-9A733A41-2543-4B6E-8DC3-EBB0419DAA19Q33712676-93111A54-94B2-46FA-B2A0-A61E784FDF88Q33720539-0205429A-4C4A-4E93-9999-2003CA5FCB2BQ33757206-B94818AD-B45B-4CE6-8229-6048B2E0D370Q33928184-DEB7A6EA-AEA3-454B-9C3F-48485D4C66F1Q33929311-8C9667D9-5657-4B62-822B-3FEB274009D2Q33976068-054B6410-EA0C-4FDB-80D5-3158BCF26B85Q33978975-4B45081D-0B4D-4E59-809B-FEAE61C74F81Q34110755-F80E8DD2-FE21-4BE8-90B0-A19D33CE78ABQ34267667-F5E339D7-69D0-42B5-B158-1C6676AE51C6Q34655810-89756B30-E5EC-49D6-AC56-62DC6AABAA3DQ34780397-ACC064BD-0B0A-4150-A540-FB5B817D44C4Q34894294-59BECDFA-0CEA-4D51-B87F-F0B12E100D67Q35069115-3A711791-B8B5-4006-9CAD-F0EA9E548EDBQ35121790-2494F27A-6D76-48A9-A160-9DA926699B3EQ35154559-66AB7311-6E0E-4D02-ACE8-BF65EFAFDF5DQ35212414-BEEBBD25-69D7-43F2-BD33-CAAD40011BF8Q35533577-89DFE82F-F121-4C7F-B162-0B532DA6D63BQ35540103-8245B86B-B0AD-436C-874C-D8339614608BQ35541212-54116A10-FB2E-4DE1-BF8D-CF6DE34D5604Q35649120-34867CC6-4A47-4A8F-9CDF-A75D5498ED15Q35692270-6FD45565-6B68-45DB-8B42-81CA8FD34B56Q35804118-0F14FD53-DBFE-4F6D-92FD-7214DA14288DQ35834198-B6BE2371-E53C-450E-8E5F-6F01BC432F2DQ35834996-8D09E915-C2B5-4CE0-9DCF-09752BF36F71Q35883504-F7F9AAE7-1E5A-4DED-9032-6FA379224B3CQ35890432-F1EFC3F8-ED06-4071-9CAF-AF670A7FBB25
P2860
Preventing antimalarial drug resistance through combinations.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Preventing antimalarial drug resistance through combinations.
@en
Preventing antimalarial drug resistance through combinations.
@nl
type
label
Preventing antimalarial drug resistance through combinations.
@en
Preventing antimalarial drug resistance through combinations.
@nl
prefLabel
Preventing antimalarial drug resistance through combinations.
@en
Preventing antimalarial drug resistance through combinations.
@nl
P1476
Preventing antimalarial drug resistance through combinations.
@en
P356
10.1016/S1368-7646(98)80208-2
P577
1998-03-01T00:00:00Z